Yuichiro Yano

Yuichiro Yano

Auto-generated profile, based on publicly available information

Yuichiro Yano

Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2018 in JAMA
Verified
Journal Article
Open access
PDF file
YYYuichiro Yano
Yuichiro Yano
JRJared P. Reis
Jared P. Reis
LCLaura A. Colangelo
Laura A. Colangelo
DSDaichi Shimbo
Daichi Shimbo
AVAnthony J. Viera
Anthony J. Viera
DLDonald M. Lloyd-Jones
Donald M. Lloyd-Jones
Quiz Ref ID The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) blood pressure (BP) guideline defined elevated BP as clinic-measured systolic BP (SBP) of 120 mm Hg to 129 mm Hg and diastolic BP (DBP) less than 80 mm Hg, and stage 1 hypertension as SBP of 130 mm Hg to 139 mm Hg or DBP of 80 mm Hg to 89 mm Hg.1 These new definitions lowered the BP thresholds for hypertension from SBP/DBP of 140/90 mm Hg or more2 to SBP/DBP of 130/80 mm Hg or more,1 and increased the prevalence of hypertension 2-fold to 3-fold among young adults.1 Quiz Ref ID Nonpharmacological and pharmacological interventions were recommended for adults with stage 1 hypertension who also have an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher. However, most young adults with stage 1 hypertension have low 10-year ASCVD risk and would not be recommended pharmacological interventions.3 Furthermore, using the Pooled Cohort Equations risk calculator to estimate 10-year ASCVD risk among adults younger than 40 years is not recommended because the equations were developed and validated among adults aged 40 to 79 years.4 If stage 1 hypertension is not associated with CVD events in young adults, it suggests the possible overdiagnosis of hypertension in this population that could result in unnecessary treatment.

10 November 2020 in Circulation
Verified
Journal Article
Open access
PDF file
KKKazuomi Kario
Kazuomi Kario
SHSatoshi Hoshide
Satoshi Hoshide
HMHiroyuki Mizuno
Hiroyuki Mizuno
TKTomoyuki Kabutoya
Tomoyuki Kabutoya
MNMasafumi Nishizawa
Masafumi Nishizawa
OGOn behalf of the JAMP Study Group
On behalf of the JAMP Study Group
Background: Ambulatory and home blood pressure (BP) monitoring parameters are better predictors of cardiovascular events than are office BP monitoring parameters, but there is a lack of robust data and little information on heart failure (HF) risk. The JAMP study (Japan Ambulatory Blood Pressure Monitoring Prospective) used the same ambulatory BP monitoring device, measurement schedule, and diary-based approach to data processing across all study centers and determined the association between both nocturnal hypertension and nighttime BP dipping patterns and the occurrence of cardiovascular events, including HF, in patients with hypertension. Methods: This practitioner-based, nationwide, multicenter, prospective, observational study included patients with at least 1 cardiovascular risk factor, mostly hypertension, and free of symptomatic cardiovascular disease at baseline. All patients underwent 24-hour ambulatory BP monitoring at baseline. Patients were followed annually to determine the occurrence of primary end point cardiovascular events (atherosclerotic cardiovascular disease and HF). Results: A total of 6,359 patients (68.6±11.7 years of age, 48% men) were included in the final analysis. During a mean±SD follow-up of 4.5±2.4 years, there were 306 cardiovascular events (119 stroke, 99 coronary artery disease, 88 HF). Nighttime systolic BP was significantly associated with the risk of atherosclerotic cardiovascular disease and HF (hazard ratio adjusted for demographic and clinical risk factors per 20-mm Hg increase: 1.21 [95% CI, 1.03–1.41], P =0.017; and 1.36 [95% CI, 1.08–1.71], P =0.009, respectively). Disrupted circadian BP rhythm (riser pattern, nighttime BP higher than daytime BP) was significantly associated with higher overall cardiovascular disease risk (1.48 [95% CI, 1.05–2.08]; P =0.024), and especially HF (2.45 [95% CI, 1.34–4.48]; P =0.004) compared with normal circadian rhythm. Conclusions: Nighttime BP levels and a riser pattern were independently associated with the total cardiovascular event rate, in particular for HF. These findings suggest the importance of antihypertensive strategies targeting nighttime systolic BP. Registration: URL: https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN000020377.

20 September 2021 in Hypertension
Verified
Journal Article
Open access
PDF file
Rianne De HeusRianne De Heus
Rianne De Heus
CTChristophe Tzourio
Christophe Tzourio
ELEmily Jo Lynn Lee
Emily Jo Lynn Lee
MOMelissa Opozda
Melissa Opozda
AVAndrew D. Vincent
Andrew D. Vincent
Phillip J TullyPhillip J Tully
Phillip J Tully
Research links high blood pressure variability (BPV) with stroke and cerebrovascular disease, however, its association with cognition remains unclear. Moreover, it remains uncertain which BP-derived parameter (ie, variability or mean) holds more significance in understanding vascular contributions to cognitive impairment. We searched PubMed, Embase, PsycINFO, and Scopus and performed a meta-analysis of studies that quantified the association between resting BPV with dementia or cognitive impairment in adults. Two authors independently reviewed all titles, abstracts, and full-texts and extracted data, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of Observational Studies in Epidemiology guidelines. Study quality was assessed using the (modified) Newcastle-Ottawa Scale. A multilevel meta-analysis was used, which included effect sizes for both BPV and mean BP, with a combined end point of dementia or cognitive impairment as primary outcome. In the primary analysis, 54 effect sizes were extracted from 20 studies, with a total analytical sample of n=7 899 697. Higher systolic BPV (odds ratio [OR], 1.25 [95% CI, 1.16–1.35]), mean systolic pressure (OR, 1.12 [95% CI, 1.02–1.29]), diastolic BPV (OR, 1.20 [95% CI, 1.12–1.29]), and mean diastolic pressure (OR, 1.16 [95% CI, 1.04–1.29]) were associated with dementia and cognitive impairment. A direct comparison showed that mean BP effect sizes were less strong than BPV effect sizes (OR, 0.92 [95% CI, 0.87–0.97], P <0.01), indicating that the relative contribution of BPV exceeded that of mean BP. Methodological and statistical heterogeneity was high. Secondary analyses were less consistent as to whether BPV and mean BP were differentially associated with dementia subtypes and cognitive domains. Future studies are required to investigate BPV as a target for dementia prevention.

8 June 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
Hidehiro KanekoHidehiro Kaneko
Hidehiro Kaneko
YYYuichiro Yano
Yuichiro Yano
HIHidetaka Itoh
Hidetaka Itoh
KMKojiro Morita
Kojiro Morita
HKHiroyuki Kiriyama
Hiroyuki Kiriyama
IKIssei Komuro
Issei Komuro
Background: Heart failure (HF) and atrial fibrillation (AF) are growing in prevalence worldwide. Few studies have assessed to what extent stage 1 hypertension in the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) blood pressure (BP) guidelines is associated with incident HF and AF. Methods: Analyses were conducted using a nationwide health claims database collected in the JMDC Claims Database between 2005 and 2018 (n=2,196,437; mean age, 44.0±10.9 years; 584% men). No participants were taking antihypertensive medication or had a known history of cardiovascular disease. Each participant was categorized as having normal BP (systolic BP [SBP]<120 mm Hg and diastolic BP [DBP]<80 mm Hg; n=1,155,885); elevated BP (SBP 120-129 mm Hg and DBP<80 mm Hg; n=337,390); stage 1 hypertension (SBP 130-139 mm Hg or DBP 80-89 mm Hg; n=459,820); or stage 2 hypertension (SBP≥140 mm Hg or DBP≥90 mm Hg; n=243,342). Using Cox proportional hazards models, we identified associations between BP groups and HF/AF events. We also calculated the population attributable fractions (PAFs) to estimate the proportion of HF and AF events that would be preventable if participants with stage 1 and stage 2 hypertension were to have normal BP. Results: Over a mean follow-up of 1,112±854 days, 28,056 incident HF and 7,774 incident AF events occurred. After multivariable adjustment, hazard ratios for HF and AF events were 1.10 (95% Confidence interval [CI], 1.05-1.15) and 1.07 (95% CI, 0.99-1.17), respectively, for elevated BP; 1.30 (95% CI, 1.26-1.35) and 1.21 (95% CI, 1.13-1.29), respectively, for stage 1 hypertension; and 2.05 (95% CI, 1.97-2.13) and 1.52 (95% CI, 1.41-1.64), respectively, for stage 2 hypertension vs normal BP. PAFs for HF associated with stage 1 and stage 2 hypertension were 23.2% (95% CI, 20.3%-26.0%) and 51.2% (95% CI, 49.2%-53.1%), respectively. The PAFs for AF associated with stage 1 and stage 2 hypertension were 17.4% (95% CI, 11.5%-22.9%) and 34.3% (95% CI, 29.1%-39.2%), respectively. Conclusions: Both stage 1 and stage 2 hypertension were associated with a greater incidence of HF and AF in the general population. The ACC/AHA BP classification system may help identify adults at higher risk for HF and AF events.

29 September 2016 in American Journal of Hypertension
Verified
Journal Article
Closed access
PDF file
YYYuichiro Yano
Yuichiro Yano
Variability is the law of life. The concept of entropy and the second law of thermodynamics suggest that systems naturally progress from order to disorder. Conversely, most biological systems appear to be homeostatic.1 However, it is obvious that biological signals, such as blood pressure (BP) and heart rate, vary in complex and irregular ways even at a steady-state condition. This is because physiological functions are a result of continuous, dynamic interactions between multiple neural, hormonal, mechanical, and local subcellular biochemical control systems.2 These physiological functions are easily altered by environmental factors, including temperature, diet, mental or physical stress, and sleep. Particularly, aging, characterized by progressive decline in tissue and organ function, has a dramatic effect on whole-body physiology. Therefore, age is a robust contributor to BP variability, both short-term (e.g., beat-to-beat and daily)...

18 October 2021 in Diabetes Care
Verified
Journal Article
Open access
PDF file
HNHajime Nagasu
Hajime Nagasu
YYYuichiro Yano
Yuichiro Yano
HKHiroshi Kanegae
Hiroshi Kanegae
HHHiddo Heerspink
Hiddo Heerspink
MNMasaomi Nangaku
Masaomi Nangaku
NKNaoki Kashihara
Naoki Kashihara
OBJECTIVE: Randomized controlled trials have shown kidney-protective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown. RESEARCH DESIGN AND METHODS: Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease. RESULTS: At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL/min per 1.73 m2, and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL/min/1.73 m2 per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26–0.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (Pheterogeneity ≥ 0.35). CONCLUSIONS: The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria.